Literature DB >> 8304844

Pleocytosis after status epilepticus.

E Barry1, W A Hauser.   

Abstract

OBJECTIVE: To determine the incidence of pleocytosis in patients experiencing status epilepticus (SE), regardless of seizure type or cause.
DESIGN: A retrospective medical chart review.
SETTING: Columbia-Presbyterian Medical Center, New York, NY. PATIENTS: Of 217 patients seen by the Neurology Service for SE during a 3-year period, 138 had a cerebrospinal fluid (CSF) analysis performed and were included in the study. All seizure types and etiologies were included. MAIN OUTCOME MEASURES: Status epilepticus was defined as a seizure or a series of continuing seizures lasting longer than 30 minutes. An abnormal CSF specimen was defined as a white blood cell (WBC) count of 6 x 10(6)/L or greater or one or more polymorphonuclear leukocytes present.
RESULTS: Overall, 22.5% of patients demonstrated abnormal WBC count or morphology. There were 21 patients (15%) with a WBC count of 6 x 10(6)/L or greater, and another 10 patients with a normal WBC count, who had polymorphonuclear leukocytes present. Among patients with illnesses usually associated with pleocytosis (such as meningitis or acute head trauma), a large proportion had abnormal CSF WBC counts. Among patients with conditions usually associated with normal CSF (including idiopathic epilepsy), a small proportion had abnormal CSF WBC counts, and the abnormalities were less severe. The highest CSF WBC count in patients with no acute insult was 28 x 10(6)/L.
CONCLUSIONS: The most important influence on the CSF WBC count is the underlying cause of the SE. Although minor elevations in WBC count can occur after SE of any type, pleocytosis should not be attributed to SE alone unless all other causes have been eliminated.

Entities:  

Mesh:

Year:  1994        PMID: 8304844     DOI: 10.1001/archneur.1994.00540140100019

Source DB:  PubMed          Journal:  Arch Neurol        ISSN: 0003-9942


  9 in total

Review 1.  Diagnosis and management of the neurological complications of falciparum malaria.

Authors:  Saroj K Mishra; Charles R J C Newton
Journal:  Nat Rev Neurol       Date:  2009-04       Impact factor: 42.937

2.  Evaluation of a clinical tool for early etiology identification in status epilepticus.

Authors:  Jong Woo Lee; Andrea O Rossetti; Vincent Alvarez; M Brandon Westover; Frank W Drislane; Barbara A Dworetzky; David Curley
Journal:  Epilepsia       Date:  2014-11-10       Impact factor: 5.864

Review 3.  [Refractory status epilepticus: diagnosis, therapy, course, and prognosis].

Authors:  F Bösebeck; G Möddel; K Anneken; M Fischera; S Evers; E B Ringelstein; C Kellinghaus
Journal:  Nervenarzt       Date:  2006-10       Impact factor: 1.214

4.  Acute childhood encephalitis and meningoencephalitis: Diagnosis and management.

Authors:  E L Ford-Jones; D Macgregor; S Richardson; F Jamieson; S Blaser; H Artsob
Journal:  Paediatr Child Health       Date:  1998-01       Impact factor: 2.253

5.  Canine cerebrospinal fluid total nucleated cell counts and cytology associations with the prevalence of magnetic resonance imaging abnormalities.

Authors:  Timothy B Hugo; Kathryn L Heading; Robert H Labuc
Journal:  Vet Med (Auckl)       Date:  2014-08-18

Review 6.  Status Epilepticus.

Authors:  Syndi Seinfeld; Howard P Goodkin; Shlomo Shinnar
Journal:  Cold Spring Harb Perspect Med       Date:  2016-03-01       Impact factor: 6.915

7.  Human cytomegalovirus (HCMV) encephalitis in an immunocompetent young person and diagnostic reliability of HCMV DNA PCR using cerebrospinal fluid of nonimmunosuppressed patients.

Authors:  S Prösch; E Schielke; A Reip; H Meisel; H D Volk; K M Einhäupl; D H Krüger
Journal:  J Clin Microbiol       Date:  1998-12       Impact factor: 5.948

Review 8.  Grand Rounds: An Update on Convulsive Status Epilepticus.

Authors:  Michael Kinney; John Craig
Journal:  Ulster Med J       Date:  2015-05

9.  New-onset refractory status epilepticus mimicking herpes virus encephalitis.

Authors:  Gianfranco Puoti; Andrea Elefante; Dario Saracino; Antonella Capasso; Roberto Cotrufo; Clara Belluomo Anello
Journal:  Case Rep Neurol       Date:  2013-09-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.